A key regulator of the neuromuscular junction, the transcriptional co-activator PGC-1α, is a potential target for Duchenne muscular dystrophy therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Kim Caesar
References
Koenig, M. et al. Cell 50, 509–517 (1987).
Nowak, K.J. & Davies, K.E. EMBO Rep. 5, 872–876 (2004).
Bogdanovich, S. et al. Nature 420, 418–421 (2002).
Khurana, T.S. & Davies, K.E. Nat. Rev. Drug Discov. 2, 379–390 (2003).
Handschin, C. et al. Genes Dev. 21, 770–783 (2007).
Sandri, M. et al. Proc. Natl. Acad. Sci. USA 103, 16260–16265 (2006).
Angus, L.M. et al. Am. J. Physiol. Cell Physiol. 289, C908–C917 (2005).
Schaeffer, L. et al. EMBO J. 17, 3078–3090 (1998).
Khurana, T.S. et al. Mol. Biol. Cell 10, 2075–2086 (1999).
Gramolini, A.O. et al. Proc. Natl. Acad. Sci. USA 96, 3223–3227 (1999).
Tinsley, J.M. et al. Nature 384, 349–353 (1996
Fredenrich, A. & Grimaldi, P.A. Diabetes and Metab. 31, 23–27 (2005).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
K.E.D. is a major shareholder of VASTox plc., a company concerned with the development of treatments for muscular dystrophy.
Rights and permissions
About this article
Cite this article
Davies, K., Khurana, T. A new way to regulate the NMJ. Nat Med 13, 538–539 (2007). https://doi.org/10.1038/nm0507-538
Issue Date:
DOI: https://doi.org/10.1038/nm0507-538
